Perceive Bio concludes Phase IIa trial enrolment for GA

​

Perceive Bio has concluded enrolment ahead of targets in its Phase IIa JOURNEY clinical study evaluating VOY-101, an experimental gene therapy for GA caused by dry AMD.

The post Perceive Bio concludes Phase IIa trial enrolment for GA appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.